MX2024005632A - Tratamiento de la depresion resistente al tratamiento con psilocibina. - Google Patents

Tratamiento de la depresion resistente al tratamiento con psilocibina.

Info

Publication number
MX2024005632A
MX2024005632A MX2024005632A MX2024005632A MX2024005632A MX 2024005632 A MX2024005632 A MX 2024005632A MX 2024005632 A MX2024005632 A MX 2024005632A MX 2024005632 A MX2024005632 A MX 2024005632A MX 2024005632 A MX2024005632 A MX 2024005632A
Authority
MX
Mexico
Prior art keywords
treatment
psilocybin
resistant depression
subject
depression
Prior art date
Application number
MX2024005632A
Other languages
English (en)
Spanish (es)
Inventor
Trevor Anthony Mill
Guy Manning Goodwin
Joyce Tsai
Lindsey Marwood
Sunil Mistry
Original Assignee
Compass Pathfinder Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Compass Pathfinder Ltd filed Critical Compass Pathfinder Ltd
Publication of MX2024005632A publication Critical patent/MX2024005632A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
MX2024005632A 2021-11-09 2022-11-02 Tratamiento de la depresion resistente al tratamiento con psilocibina. MX2024005632A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163277407P 2021-11-09 2021-11-09
US202163284973P 2021-12-01 2021-12-01
PCT/US2022/048713 WO2023086252A1 (en) 2021-11-09 2022-11-02 Treatment of treatment resistant depression with psilocybin

Publications (1)

Publication Number Publication Date
MX2024005632A true MX2024005632A (es) 2024-07-29

Family

ID=84799979

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024005632A MX2024005632A (es) 2021-11-09 2022-11-02 Tratamiento de la depresion resistente al tratamiento con psilocibina.

Country Status (8)

Country Link
US (1) US20250000881A1 (cg-RX-API-DMAC7.html)
EP (1) EP4429671A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024543379A (cg-RX-API-DMAC7.html)
KR (1) KR20240110816A (cg-RX-API-DMAC7.html)
AU (1) AU2022387053A1 (cg-RX-API-DMAC7.html)
CA (1) CA3237885A1 (cg-RX-API-DMAC7.html)
MX (1) MX2024005632A (cg-RX-API-DMAC7.html)
WO (1) WO2023086252A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2571696B (en) 2017-10-09 2020-05-27 Compass Pathways Ltd Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
KR20220008824A (ko) 2019-04-17 2022-01-21 컴퍼스 패쓰파인더 리미티드 실로시빈으로 불안 장애, 두통 장애 및 섭식 장애를 치료하는 방법
MX2023011326A (es) * 2021-03-30 2023-10-03 Compass Pathfinder Ltd Composiciones de psilocibina, metodos para prepararlas y metodos de uso de estas.
WO2023168023A1 (en) 2022-03-04 2023-09-07 Reset Pharmaceuticals, Inc. Co-crystals or salts comprising psilocin

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2588505B (en) * 2017-10-09 2022-08-03 Compass Pathfinder Ltd Preparation of psilocybin
GB2571696B (en) * 2017-10-09 2020-05-27 Compass Pathways Ltd Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
KR20220008824A (ko) * 2019-04-17 2022-01-21 컴퍼스 패쓰파인더 리미티드 실로시빈으로 불안 장애, 두통 장애 및 섭식 장애를 치료하는 방법
MX2023011326A (es) * 2021-03-30 2023-10-03 Compass Pathfinder Ltd Composiciones de psilocibina, metodos para prepararlas y metodos de uso de estas.

Also Published As

Publication number Publication date
EP4429671A1 (en) 2024-09-18
KR20240110816A (ko) 2024-07-16
JP2024543379A (ja) 2024-11-21
WO2023086252A1 (en) 2023-05-19
US20250000881A1 (en) 2025-01-02
AU2022387053A1 (en) 2024-05-09
CA3237885A1 (en) 2023-05-19

Similar Documents

Publication Publication Date Title
MX2023000735A (es) Metodos y combinaciones de inhibidor de kat6 para el tratamiento del cancer.
BR112021024310A2 (pt) Peptidomiméticos para o tratamento de infecções por coronavírus e picornavírus
CL2020002512A1 (es) Tratamiento de la hidradenitis supurativa mediante el uso de inhibidores de jak.
CL2024003040A1 (es) Tratamientos del cáncer con inhibidores de prmt5 cooperativos con mta
BR112023006364A2 (pt) Terapia de combinação de imuno-oncologia com conjugados de il-2 e pembrolizumabe
PE20230996A1 (es) Metodo para el tratamiento de afecciones asociadas a covid-19
MX2020001768A (es) Metodos de tratamiento de la osteoartritis con gel de canabidiol transdermico.
MX2022010357A (es) Anticuerpos inhibidores de anti-pcsk9 para el tratamiento de pacientes con hiperlipidemia que se someten aferesis de lipoproteina.
MX2023004554A (es) Uso de benzodiazepinas para aumentar la sensibilidad a la psilocibina despues de un regimen cronico de isrs.
CO2022014388A2 (es) Una terapia combinada con nirogacestat y una terapia dirigida a bcma y usos de estas
MX2016011975A (es) Metodos para reducir el riesgo cardiovascular.
MX2013005564A (es) Medicamentos de canabinoides en bajas dosis.
MX2020013163A (es) Metodos para tratar trastornos linfoproliferativos malignos.
CL2018002734A1 (es) Métodos de tratamiento con vitamina d
WO2021211940A8 (en) Methods for treating a complement mediated disorder caused by viruses
AR120055A1 (es) Métodos para tratar la enfermedad de fabry en pacientes que tienen insuficiencia renal
CR20210514A (es) USO DE REBOXETINA PARA EL TRATAMIENTO DE NARCOLEPSIA (Divisional 2021-0183)
CO2024012870A2 (es) Tratamiento de neurofibromas cutáneos con mirdametinib
MX2025014865A (es) Metodos para tratar el cancer o enfermedad de von-hippel lindau usando una combinacion de un inhibidor de hif-2 alpha y lenvatinib
BR112022022599A2 (pt) Métodos de tratamento de covid-19 usando bardoxolona metil ou análogos da mesma
CL2021001976A1 (es) Tratamiento de lesiones cutáneas y prurito en pacientes con prurigo nodular
MX2021004463A (es) Terapia de disminución de arginina para el tratamiento de la deficiencia de gamt.
MX2023015097A (es) Tratamiento de sintomas asociados a neoplasias mieloproliferativas.
MX2022004449A (es) Dosis y usos de fenilacetato de ornitina para el tratamiento de hiperamonemia.
CO2022007501A2 (es) Métodos y composiciones para el tratamiento del síndrome de rett